39,655 Boston Scientific Corporation $BSX Shares Sold by Asset Management One Co. Ltd.

Key Points

• Asset Management One reduced its Boston Scientific stake by 5.9%, selling 39,655 shares and retaining 638,076 shares valued at approximately $27.9 million. Institutional investors and hedge funds collectively own 89.07% of the company.
• Boston Scientific reported quarterly earnings of $0.73 per share, in line with estimates, while revenue of $5.14 billion exceeded expectations and rose 1.4% year over year. However, cybersecurity disruptions and other operational challenges pressured the outlook.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $61.87 target price, although several firms recently lowered targets or shifted to more cautious ratings. Company insiders bought roughly $9.2 million of shares over the past 90 days.

Asset Management One Co. Ltd. decreased its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 5.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 638,076 shares of the medical equipment provider's stock after selling 39,655 shares during the period. Asset Management One Co. Ltd.'s holdings in Boston Scientific were worth $27,852,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $5,534,781,000. Primecap Management Co. CA acquired a new stake in Boston Scientific during the 2nd quarter valued at $2,156,233,000. Jupiter Topco LLC bought a new position in Boston Scientific during the second quarter worth $803,357,000. Bank of America Corp DE bought a new position in Boston Scientific during the second quarter worth $556,026,000. Finally, Legal & General Group Plc acquired a new position in shares of Boston Scientific in the second quarter valued at $431,890,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Piper Sandler dropped their price objective on shares of Boston Scientific from $65.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 29th. Needham & Company LLC reduced their target price on shares of Boston Scientific from $57.00 to $48.00 and set a "buy" rating for the company in a report on Wednesday. JPMorgan Chase & Co. lowered shares of Boston Scientific from an "overweight" rating to a "neutral" rating and set a $46.00 price target on the stock. in a research note on Wednesday. Citigroup lowered their price target on shares of Boston Scientific from $48.00 to $44.00 and set a "neutral" rating on the stock in a report on Thursday. Finally, Evercore cut their price objective on shares of Boston Scientific from $65.00 to $52.00 and set an "outperform" rating for the company in a research report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $61.87.

Boston Scientific Stock Performance

NYSE BSX opened at $42.69 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $61.86 billion, a P/E ratio of 18.09, a P/E/G ratio of 1.04 and a beta of 0.58. Boston Scientific Corporation has a 12-month low of $39.57 and a 12-month high of $105.65. The firm has a 50-day moving average price of $44.93 and a two-hundred day moving average price of $57.15.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting analysts' consensus estimates of $0.73. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The firm's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.75 earnings per share. Analysts anticipate that Boston Scientific Corporation will post 3.18 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director David C. Habiger bought 2,100 shares of the business's stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney bought 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 189,522 shares of company stock worth $9,157,810. Corporate insiders own 0.34% of the company's stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Third-quarter revenue increased 1.5% year over year to $5.138 billion, topping the $5.07 billion consensus estimate, while adjusted earnings of $0.73 per share matched expectations. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Robert W. Baird raised its price target from $50 to $51 and maintained an “outperform” rating, while BTIG, UBS and Sanford C. Bernstein retained bullish ratings despite lowering their targets. Analysts revise forecasts after Q3 results
• Positive Sentiment: Management pointed to long-term growth initiatives, including Elite AF trial enrollment and FDA clearances for StoneSmart and SEISMIQ catheter technologies. Recent insider activity also showed purchases rather than sales, offering a modest confidence signal.
• Neutral Sentiment: Boston Scientific expects approximately 4.25% reported full-year 2026 sales growth, but forecast fourth-quarter reported and organic sales declines of 1% to 3%. Boston Scientific cuts view again after cyberattack
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by roughly $150 million and continues to affect operations, customer activity and the recovery timeline.
• Negative Sentiment: Management lowered full-year adjusted EPS guidance to $3.16-$3.18, below investor expectations, and warned that growth could remain broadly flat in 2027 as EP and WATCHMAN weakness, China pricing pressure and product-related challenges persist. BSX Q3 earnings call flags growth challenges
• Negative Sentiment: Analyst sentiment became more cautious: Oppenheimer downgraded BSX to “market perform,” JPMorgan moved to “neutral,” and multiple firms cut price targets, including Wells Fargo to $45 and Needham to $48.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.